Novo files a higher 7.2 mg dose of Wegovy with the FDA

Novo Nordisk submitted a US application for a higher-dose version of Wegovy, semaglutide 7.2 mg, after a late-stage trial called STEP UP found that people on the higher dose lost more weight than those on the current top dose of 2.4 mg ^[1][2]. The filing was later folded into the FDA's new Commissioner's National Priority Voucher pilot program, which sped up the review ^[2].

In the STEP UP trial, which enrolled 1,407 adults with obesity over 72 weeks, people taking semaglutide 7.2 mg lost an average of 18.7% of their starting body weight, compared with 3.9% for those on placebo ^[2]. Nearly one in three participants, 31.2%, lost 25% or more of their body weight ^[2]. A related trial in people with obesity and type 2 diabetes, called STEP UP T2D and enrolling about 512 adults, found the 7.2 mg dose produced 13.2% average weight loss versus placebo, with 21.3% of patients losing 20% or more ^[2]. Novo Nordisk has cited an overall figure of 20.7% mean weight loss with the higher dose, and separate reporting says people who lost weight and stayed on treatment the full trial period lost close to 21% ^[1][2].

Side effects with the 7.2 mg dose looked similar to those seen with existing semaglutide doses, mostly gastrointestinal issues like nausea, but one side effect stood out. Dysesthesia, an abnormal skin sensation, was reported in 18.9% of people on 7.2 mg in the diabetes trial, compared with 4.9% on 2.4 mg and 0% on placebo ^[2].

The FDA approved the higher dose, marketed as Wegovy HD, making it the fourth drug cleared under the National Priority Voucher program, according to FDA Commissioner Martin Makary ^[2]. Novo Nordisk expects a US launch of a single-dose pen in April 2026 ^[2]. The dose is already approved in the European Union and the United Kingdom ^[2].

Why it matters for patients

For people whose weight loss has plateaued on the current top Wegovy dose of 2.4 mg, a 7.2 mg option could offer a way to lose more weight without switching to a different drug class or considering bariatric surgery ^[2]. Novo Nordisk's CEO, Mike Doustdar, described it as a step up within the same drug, following the January 2026 launch of the Wegovy pill ^[1][2].

The tradeoff is a higher rate of dysesthesia and the same gastrointestinal side effects already common with semaglutide, so people considering the higher dose and their clinicians will need to weigh added weight loss against these effects ^[2]. It is not yet known from these sources how insurers will price or cover Wegovy HD compared with the 2.4 mg version, or how quickly pharmacies will stock it after the April 2026 launch ^[2].

What happens next

Wegovy HD is expected to launch in the US in a single-dose pen in April 2026, joining Novo Nordisk's existing Wegovy lineup, which already includes a once-daily 25 mg pill and once-weekly injections at 1.7 mg and 2.4 mg ^[2]. Broader industry coverage suggests 2026 will also bring other changes to the GLP-1 market, including a possible decision on the pill-form GLP-1 orforglipron in the second quarter of 2026 and an FDA response on the combination drug CagriSema sometime in the year, though those developments involve different companies and drugs ^[1].